<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34820735</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>269</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.</ArticleTitle>
        <Pagination>
          <StartPage>3136</StartPage>
          <EndPage>3146</EndPage>
          <MedlinePgn>3136-3146</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10914-x</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The patterns of relapse and relapse-prevention strategies for anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are not completely investigated. We compared the patterns of relapse in later stages of MOGAD with those of anti-aquaporin-4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this observational, comparative cohort study, 66 patients with MOGAD and 90 with AQP4-Ab-positive NMOSD were enrolled. We compared the patterns of relapse and annualized relapse rates (ARRs) in the first 10 years from disease onset, stratified by relapse-prevention treatments.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Approximately 50% of the patients with MOGAD experienced relapses in the first 10 years. Among those not undergoing relapse-prevention treatments, ARRs in the first 5 years were slightly lower in MOGAD patients than in AQP4-Ab-positive NMOSD patients (MOGAD vs. AQP4-Ab NMOSD: 0.19 vs. 0.30; p = 0.0753). After 5 years, the ARR decreased in MOGAD patients (MOGAD vs. AQP4-Ab NMOSD: 0.05 vs. 0.34; p = 0.0001), with a 72% reduction from the first 5 years (p = 0.0090). Eight (61.5%) of the 13 MOGAD patients with more than 10-year follow-up from disease onset showed relapse 10 years after onset. Clustering in the timing and phenotype of attacks was observed in both disease patients. The effectiveness of long-term low-dose oral PSL for relapse prevention in patients with MOGAD has not been determined.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The relapse risk in patients with MOGAD is generally lower than that in patients with AQP4-Ab-positive NMOSD, especially 5 years after onset. Meanwhile, relapses later than 10 years from onset are not rare in both diseases.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Akaishi</LastName>
            <ForeName>Tetsuya</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-6728-4966</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. t-akaishi@med.tohoku.ac.jp.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan. t-akaishi@med.tohoku.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Misu</LastName>
            <ForeName>Tatsuro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujihara</LastName>
            <ForeName>Kazuo</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Toshiyuki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takai</LastName>
            <ForeName>Yoshiki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishiyama</LastName>
            <ForeName>Shuhei</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaneko</LastName>
            <ForeName>Kimihiko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujimori</LastName>
            <ForeName>Juichi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishii</LastName>
            <ForeName>Tadashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aoki</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakashima</LastName>
            <ForeName>Ichiro</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>FC001030</GrantID>
            <Acronym>ARC_</Acronym>
            <Agency>Arthritis Research UK</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D063308">Myelin-Oligodendrocyte Glycoprotein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000719032">anti-aquaporin 4 autoantibody</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="Y">Aquaporin 4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063308" MajorTopicYN="N">Myelin-Oligodendrocyte Glycoprotein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-myelin oligodendrocyte glycoprotein (MOG) antibody</Keyword>
        <Keyword MajorTopicYN="N">MOG-antibody-associated disease (MOGAD)</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis optica spectrum disorder (NMOSD)</Keyword>
        <Keyword MajorTopicYN="N">Relapse prevention</Keyword>
        <Keyword MajorTopicYN="N">Relapse-free survival</Keyword>
      </KeywordList>
      <CoiStatement>T. Akaishi, T. Misu, T. Takahashi, Y. Takai, S. Nishiyama, K. Kaneko, J. Fujimori, T. Ishii, and M. Aoki report no disclosures. K. Fujihara received speaker honoraria and travel funding from Bayer, Biogen Japan, Eisai, Mitsubishi Tanabe, Novartis, Astellas, Takeda, Asahi Kasei Medical, Daiichi Sankyo, and Nihon Pharmaceutical, and received research support from Bayer, Biogen, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva, Mitsubishi Tanabe Pharma, Teijin, Chugai, Ono, Nihon Pharmaceutical, and Genzyme. I. Nakashima received speaker honoraria, travel funding, and advisory fee from Biogen Japan, Novartis Pharma, Alexion Pharma, and Chugai Pharmaceutical and received research support from LSI Medience.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34820735</ArticleId>
        <ArticleId IdType="pmc">PMC9120114</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-021-10914-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-021-10914-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al.  Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501. doi: 10.3389/fneur.2020.00501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00501</ArticleId>
            <ArticleId IdType="pmc">PMC7332882</ArticleId>
            <ArticleId IdType="pubmed">32670177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65:1479–1482. doi: 10.1212/01.wnl.0000183151.19351.82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000183151.19351.82</ArticleId>
            <ArticleId IdType="pubmed">16275842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189. doi: 10.1212/WNL.0000000000001729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001729</ArticleId>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci. 2016;1366:20–39. doi: 10.1111/nyas.12794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.12794</ArticleId>
            <ArticleId IdType="pmc">PMC4675706</ArticleId>
            <ArticleId IdType="pubmed">26096370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477. doi: 10.1084/jem.20050304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050304</ArticleId>
            <ArticleId IdType="pmc">PMC2212860</ArticleId>
            <ArticleId IdType="pubmed">16087714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, et al.  MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol. 2018;9:217. doi: 10.3389/fneur.2018.00217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.00217</ArticleId>
            <ArticleId IdType="pmc">PMC5893792</ArticleId>
            <ArticleId IdType="pubmed">29670575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tajfirouz DA, Bhatti MT, Chen JJ. Clinical characteristics and treatment of MOG-IgG-associated optic neuritis. Curr Neurol Neurosci Rep. 2019;19:100. doi: 10.1007/s11910-019-1014-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11910-019-1014-z</ArticleId>
            <ArticleId IdType="pubmed">31773369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Pauli F, Berger T. Myelin oligodendrocyte glycoprotein antibody-associated disorders: toward a new spectrum of inflammatory demyelinating CNS disorders? Front Immunol. 2018;9:2753. doi: 10.3389/fimmu.2018.02753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02753</ArticleId>
            <ArticleId IdType="pmc">PMC6281762</ArticleId>
            <ArticleId IdType="pubmed">30555462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33:47–54. doi: 10.1097/WCO.0000000000000766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000766</ArticleId>
            <ArticleId IdType="pubmed">31743235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cobo-Calvo A, Marignier R. MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - no. Mult Scler. 2020;26:274–276. doi: 10.1177/1352458519863135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458519863135</ArticleId>
            <ArticleId IdType="pubmed">31842679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Sato DK. MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - yes. Mult Scler. 2020;26:272–274. doi: 10.1177/1352458519868796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458519868796</ArticleId>
            <ArticleId IdType="pubmed">31842686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, et al.  Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder. Neurology. 2021;97:e1–e12. doi: 10.1212/WNL.0000000000012175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000012175</ArticleId>
            <ArticleId IdType="pmc">PMC8312856</ArticleId>
            <ArticleId IdType="pubmed">33980704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon YN, Kim B, Kim JS, Mo H, Choi K, Oh SI, et al.  Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflammation. 2022;9:e1095. doi: 10.1212/NXI.0000000000001095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000001095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282. doi: 10.1186/s12974-016-0720-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0720-6</ArticleId>
            <ArticleId IdType="pmc">PMC5088645</ArticleId>
            <ArticleId IdType="pubmed">27802824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, et al.  Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS One. 2017;12:e0170847. doi: 10.1371/journal.pone.0170847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0170847</ArticleId>
            <ArticleId IdType="pmc">PMC5268377</ArticleId>
            <ArticleId IdType="pubmed">28125740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280. doi: 10.1186/s12974-016-0718-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0718-0</ArticleId>
            <ArticleId IdType="pmc">PMC5086042</ArticleId>
            <ArticleId IdType="pubmed">27793206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaishi T, Takahashi T, Misu T, Abe M, Ishii T, Fujimori J, et al.  Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci Rep. 2020;10:13890. doi: 10.1038/s41598-020-70919-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-70919-w</ArticleId>
            <ArticleId IdType="pmc">PMC7431838</ArticleId>
            <ArticleId IdType="pubmed">32807848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics. 2016;13:70–83. doi: 10.1007/s13311-015-0400-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-015-0400-8</ArticleId>
            <ArticleId IdType="pmc">PMC4720663</ArticleId>
            <ArticleId IdType="pubmed">26597098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al.  Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS) J Neurol. 2014;261:1–16. doi: 10.1007/s00415-013-7169-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-7169-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflammation. 2015;2:e110. doi: 10.1212/NXI.0000000000000110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, et al.  Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372–1378. doi: 10.1001/jamaneurol.2014.2057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.2057</ArticleId>
            <ArticleId IdType="pubmed">25199960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110–1117. doi: 10.1001/jamaneurol.2013.3071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.3071</ArticleId>
            <ArticleId IdType="pubmed">23897062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al.  Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20:1533–1540. doi: 10.1177/1352458514525870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514525870</ArticleId>
            <ArticleId IdType="pubmed">24647557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al.  Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–625. doi: 10.1056/NEJMoa1900866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1900866</ArticleId>
            <ArticleId IdType="pubmed">31050279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, et al.  Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord. 2021;49:102750. doi: 10.1016/j.msard.2021.102750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2021.102750</ArticleId>
            <ArticleId IdType="pubmed">33524925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, et al.  Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756–763. doi: 10.1001/jamaneurol.2015.0533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2015.0533</ArticleId>
            <ArticleId IdType="pubmed">25985228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaishi T, Nakashima I, Takahashi T, Abe M, Ishii T, Aoki M. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflammation. 2020;7:e640. doi: 10.1212/NXI.0000000000000640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al.  Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130:1235–1243. doi: 10.1093/brain/awm062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awm062</ArticleId>
            <ArticleId IdType="pubmed">17449477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474–481. doi: 10.1212/WNL.0000000000000101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000101</ArticleId>
            <ArticleId IdType="pmc">PMC3937859</ArticleId>
            <ArticleId IdType="pubmed">24415568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox DR. Some simple tests for poisson variates. Biometrika. 1953;40:354–360. doi: 10.1093/biomet/40.3-4.354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/biomet/40.3-4.354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clayton D. Some approaches to the analysis of recurrent event data. Stat Methods Med Res. 1994;3:244–262. doi: 10.1177/096228029400300304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/096228029400300304</ArticleId>
            <ArticleId IdType="pubmed">7820294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al.  Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23:1377–1384. doi: 10.1177/1352458516678474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458516678474</ArticleId>
            <ArticleId IdType="pubmed">27885065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol. 2019;31:250–255. doi: 10.1097/BOR.0000000000000603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0000000000000603</ArticleId>
            <ArticleId IdType="pubmed">30920972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008;10:55–66. doi: 10.1007/s11940-008-0007-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11940-008-0007-z</ArticleId>
            <ArticleId IdType="pubmed">18325300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567:305–307. doi: 10.1038/d41586-019-00857-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41586-019-00857-9</ArticleId>
            <ArticleId IdType="pubmed">30894741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waters P, Woodhall M, O'Connor KC, Reindl M, Lang B, Sato DK, et al.  MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflammation. 2015;2:e89. doi: 10.1212/NXI.0000000000000089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000089</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34820735</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>269</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.</ArticleTitle>
        <Pagination>
          <StartPage>3136</StartPage>
          <EndPage>3146</EndPage>
          <MedlinePgn>3136-3146</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10914-x</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The patterns of relapse and relapse-prevention strategies for anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are not completely investigated. We compared the patterns of relapse in later stages of MOGAD with those of anti-aquaporin-4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this observational, comparative cohort study, 66 patients with MOGAD and 90 with AQP4-Ab-positive NMOSD were enrolled. We compared the patterns of relapse and annualized relapse rates (ARRs) in the first 10 years from disease onset, stratified by relapse-prevention treatments.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Approximately 50% of the patients with MOGAD experienced relapses in the first 10 years. Among those not undergoing relapse-prevention treatments, ARRs in the first 5 years were slightly lower in MOGAD patients than in AQP4-Ab-positive NMOSD patients (MOGAD vs. AQP4-Ab NMOSD: 0.19 vs. 0.30; p = 0.0753). After 5 years, the ARR decreased in MOGAD patients (MOGAD vs. AQP4-Ab NMOSD: 0.05 vs. 0.34; p = 0.0001), with a 72% reduction from the first 5 years (p = 0.0090). Eight (61.5%) of the 13 MOGAD patients with more than 10-year follow-up from disease onset showed relapse 10 years after onset. Clustering in the timing and phenotype of attacks was observed in both disease patients. The effectiveness of long-term low-dose oral PSL for relapse prevention in patients with MOGAD has not been determined.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The relapse risk in patients with MOGAD is generally lower than that in patients with AQP4-Ab-positive NMOSD, especially 5 years after onset. Meanwhile, relapses later than 10 years from onset are not rare in both diseases.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Akaishi</LastName>
            <ForeName>Tetsuya</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-6728-4966</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. t-akaishi@med.tohoku.ac.jp.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan. t-akaishi@med.tohoku.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Misu</LastName>
            <ForeName>Tatsuro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujihara</LastName>
            <ForeName>Kazuo</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Toshiyuki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takai</LastName>
            <ForeName>Yoshiki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishiyama</LastName>
            <ForeName>Shuhei</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaneko</LastName>
            <ForeName>Kimihiko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujimori</LastName>
            <ForeName>Juichi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishii</LastName>
            <ForeName>Tadashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aoki</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakashima</LastName>
            <ForeName>Ichiro</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>FC001030</GrantID>
            <Acronym>ARC_</Acronym>
            <Agency>Arthritis Research UK</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D063308">Myelin-Oligodendrocyte Glycoprotein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000719032">anti-aquaporin 4 autoantibody</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="Y">Aquaporin 4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063308" MajorTopicYN="N">Myelin-Oligodendrocyte Glycoprotein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-myelin oligodendrocyte glycoprotein (MOG) antibody</Keyword>
        <Keyword MajorTopicYN="N">MOG-antibody-associated disease (MOGAD)</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis optica spectrum disorder (NMOSD)</Keyword>
        <Keyword MajorTopicYN="N">Relapse prevention</Keyword>
        <Keyword MajorTopicYN="N">Relapse-free survival</Keyword>
      </KeywordList>
      <CoiStatement>T. Akaishi, T. Misu, T. Takahashi, Y. Takai, S. Nishiyama, K. Kaneko, J. Fujimori, T. Ishii, and M. Aoki report no disclosures. K. Fujihara received speaker honoraria and travel funding from Bayer, Biogen Japan, Eisai, Mitsubishi Tanabe, Novartis, Astellas, Takeda, Asahi Kasei Medical, Daiichi Sankyo, and Nihon Pharmaceutical, and received research support from Bayer, Biogen, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva, Mitsubishi Tanabe Pharma, Teijin, Chugai, Ono, Nihon Pharmaceutical, and Genzyme. I. Nakashima received speaker honoraria, travel funding, and advisory fee from Biogen Japan, Novartis Pharma, Alexion Pharma, and Chugai Pharmaceutical and received research support from LSI Medience.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34820735</ArticleId>
        <ArticleId IdType="pmc">PMC9120114</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-021-10914-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-021-10914-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al.  Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501. doi: 10.3389/fneur.2020.00501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00501</ArticleId>
            <ArticleId IdType="pmc">PMC7332882</ArticleId>
            <ArticleId IdType="pubmed">32670177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65:1479–1482. doi: 10.1212/01.wnl.0000183151.19351.82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000183151.19351.82</ArticleId>
            <ArticleId IdType="pubmed">16275842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189. doi: 10.1212/WNL.0000000000001729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001729</ArticleId>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci. 2016;1366:20–39. doi: 10.1111/nyas.12794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.12794</ArticleId>
            <ArticleId IdType="pmc">PMC4675706</ArticleId>
            <ArticleId IdType="pubmed">26096370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477. doi: 10.1084/jem.20050304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050304</ArticleId>
            <ArticleId IdType="pmc">PMC2212860</ArticleId>
            <ArticleId IdType="pubmed">16087714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, et al.  MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol. 2018;9:217. doi: 10.3389/fneur.2018.00217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.00217</ArticleId>
            <ArticleId IdType="pmc">PMC5893792</ArticleId>
            <ArticleId IdType="pubmed">29670575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tajfirouz DA, Bhatti MT, Chen JJ. Clinical characteristics and treatment of MOG-IgG-associated optic neuritis. Curr Neurol Neurosci Rep. 2019;19:100. doi: 10.1007/s11910-019-1014-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11910-019-1014-z</ArticleId>
            <ArticleId IdType="pubmed">31773369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Pauli F, Berger T. Myelin oligodendrocyte glycoprotein antibody-associated disorders: toward a new spectrum of inflammatory demyelinating CNS disorders? Front Immunol. 2018;9:2753. doi: 10.3389/fimmu.2018.02753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02753</ArticleId>
            <ArticleId IdType="pmc">PMC6281762</ArticleId>
            <ArticleId IdType="pubmed">30555462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33:47–54. doi: 10.1097/WCO.0000000000000766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000766</ArticleId>
            <ArticleId IdType="pubmed">31743235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cobo-Calvo A, Marignier R. MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - no. Mult Scler. 2020;26:274–276. doi: 10.1177/1352458519863135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458519863135</ArticleId>
            <ArticleId IdType="pubmed">31842679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Sato DK. MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - yes. Mult Scler. 2020;26:272–274. doi: 10.1177/1352458519868796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458519868796</ArticleId>
            <ArticleId IdType="pubmed">31842686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, et al.  Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder. Neurology. 2021;97:e1–e12. doi: 10.1212/WNL.0000000000012175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000012175</ArticleId>
            <ArticleId IdType="pmc">PMC8312856</ArticleId>
            <ArticleId IdType="pubmed">33980704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon YN, Kim B, Kim JS, Mo H, Choi K, Oh SI, et al.  Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflammation. 2022;9:e1095. doi: 10.1212/NXI.0000000000001095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000001095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282. doi: 10.1186/s12974-016-0720-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0720-6</ArticleId>
            <ArticleId IdType="pmc">PMC5088645</ArticleId>
            <ArticleId IdType="pubmed">27802824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, et al.  Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS One. 2017;12:e0170847. doi: 10.1371/journal.pone.0170847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0170847</ArticleId>
            <ArticleId IdType="pmc">PMC5268377</ArticleId>
            <ArticleId IdType="pubmed">28125740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280. doi: 10.1186/s12974-016-0718-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0718-0</ArticleId>
            <ArticleId IdType="pmc">PMC5086042</ArticleId>
            <ArticleId IdType="pubmed">27793206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaishi T, Takahashi T, Misu T, Abe M, Ishii T, Fujimori J, et al.  Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci Rep. 2020;10:13890. doi: 10.1038/s41598-020-70919-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-70919-w</ArticleId>
            <ArticleId IdType="pmc">PMC7431838</ArticleId>
            <ArticleId IdType="pubmed">32807848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics. 2016;13:70–83. doi: 10.1007/s13311-015-0400-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-015-0400-8</ArticleId>
            <ArticleId IdType="pmc">PMC4720663</ArticleId>
            <ArticleId IdType="pubmed">26597098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al.  Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS) J Neurol. 2014;261:1–16. doi: 10.1007/s00415-013-7169-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-7169-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflammation. 2015;2:e110. doi: 10.1212/NXI.0000000000000110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, et al.  Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372–1378. doi: 10.1001/jamaneurol.2014.2057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.2057</ArticleId>
            <ArticleId IdType="pubmed">25199960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110–1117. doi: 10.1001/jamaneurol.2013.3071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.3071</ArticleId>
            <ArticleId IdType="pubmed">23897062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al.  Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20:1533–1540. doi: 10.1177/1352458514525870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514525870</ArticleId>
            <ArticleId IdType="pubmed">24647557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al.  Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–625. doi: 10.1056/NEJMoa1900866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1900866</ArticleId>
            <ArticleId IdType="pubmed">31050279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, et al.  Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord. 2021;49:102750. doi: 10.1016/j.msard.2021.102750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2021.102750</ArticleId>
            <ArticleId IdType="pubmed">33524925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, et al.  Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756–763. doi: 10.1001/jamaneurol.2015.0533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2015.0533</ArticleId>
            <ArticleId IdType="pubmed">25985228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaishi T, Nakashima I, Takahashi T, Abe M, Ishii T, Aoki M. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflammation. 2020;7:e640. doi: 10.1212/NXI.0000000000000640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al.  Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130:1235–1243. doi: 10.1093/brain/awm062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awm062</ArticleId>
            <ArticleId IdType="pubmed">17449477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474–481. doi: 10.1212/WNL.0000000000000101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000101</ArticleId>
            <ArticleId IdType="pmc">PMC3937859</ArticleId>
            <ArticleId IdType="pubmed">24415568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox DR. Some simple tests for poisson variates. Biometrika. 1953;40:354–360. doi: 10.1093/biomet/40.3-4.354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/biomet/40.3-4.354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clayton D. Some approaches to the analysis of recurrent event data. Stat Methods Med Res. 1994;3:244–262. doi: 10.1177/096228029400300304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/096228029400300304</ArticleId>
            <ArticleId IdType="pubmed">7820294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al.  Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23:1377–1384. doi: 10.1177/1352458516678474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458516678474</ArticleId>
            <ArticleId IdType="pubmed">27885065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol. 2019;31:250–255. doi: 10.1097/BOR.0000000000000603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0000000000000603</ArticleId>
            <ArticleId IdType="pubmed">30920972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008;10:55–66. doi: 10.1007/s11940-008-0007-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11940-008-0007-z</ArticleId>
            <ArticleId IdType="pubmed">18325300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567:305–307. doi: 10.1038/d41586-019-00857-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41586-019-00857-9</ArticleId>
            <ArticleId IdType="pubmed">30894741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waters P, Woodhall M, O'Connor KC, Reindl M, Lang B, Sato DK, et al.  MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflammation. 2015;2:e89. doi: 10.1212/NXI.0000000000000089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000089</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
